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OBJECTIVE—Prevention of diabetic retinopathy would beneﬁt
from availability of drugs that preempt the effects of hyperglyce-
mia on retinal vessels. We aimed to identify candidate drug
targets by investigating the molecular effects of drugs that
prevent retinal capillary demise in the diabetic rat.
RESEARCH DESIGN AND METHODS—We examined the
gene expression proﬁle of retinal vessels isolated from rats with
6 months of streptozotocin-induced diabetes and compared it
with that of control rats. We then tested whether the aldose
reductase inhibitor sorbinil and aspirin, which have different
mechanisms of action, prevented common molecular abnormal-
ities induced by diabetes. The Affymetrix GeneChip Rat Genome
230 2.0 array was complemented by real-time RT-PCR, immuno-
blotting, and immunohistochemistry.
RESULTS—The retinal vessels of diabetic rats showed differen-
tial expression of 20 genes of the transforming growth factor
(TGF)- pathway, in addition to genes involved in oxidative
stress, inﬂammation, vascular remodeling, and apoptosis. The
complete loop of TGF- signaling, including Smad2 phosphory-
lation, was enhanced in the retinal vessels, but not in the neural
retina. Sorbinil normalized the expression of 71% of the genes
related to oxidative stress and 62% of those related to inﬂamma-
tion. Aspirin had minimal or no effect on these two categories.
The two drugs were instead concordant in reducing the upregu-
lation of genes of the TGF- pathway (55% for sorbinil and 40%
for aspirin) and apoptosis (74 and 42%, respectively).
CONCLUSIONS—Oxidative and inﬂammatory stress is the dis-
tinct signature that the polyol pathway leaves on retinal vessels.
TGF- and apoptosis are, however, the ultimate targets to
prevent the capillary demise in diabetic retinopathy. Diabetes
58:1659–1667, 2009
T
he clinical manifestations of diabetic retinopathy
are consequences of a microangiopathy where
retinal capillaries develop thickened basement
membranes, lose pericytes and endothelial cells
by accelerated apoptosis, form microaneurysms, become
abnormally permeable, and eventually are transformed
into acellular tubes of basement membrane no longer
perfused (1–3). When a critical number of capillaries are
affected, retinal edema and/or ischemia ensue. In princi-
ple, prevention should be attainable with correction of the
hyperglycemia, but is not being attained today because the
means of treating diabetes are still imperfect and do not
easily maintain normoglycemia. Thus, retinopathy and its
sight-threatening features continue to occur even among
patients treated intensively (4).
There is an outstanding need for drugs that complement
antidiabetic treatment by limiting the effects of residual
hyperglycemia on retinal vessels. No such drugs are avail-
able for clinical use, even though several have been tested
in human diabetic retinopathy. The clinical trials per-
formed to date may have failed because the drugs were
given too late, for too short a period, and/or at ineffective
doses (5), but also because the drug targets may have been
irrelevant to human diabetic retinopathy. These consider-
ations encourage the development of approaches that
would limit the risk of both false-negative and true-
negative trials in the future.
One such approach could be to identify the molecular
processes that are causally linked to retinal microangiopa-
thy in animal models and then test whether the processes
are active in human diabetic retinopathy and therefore
represent efﬁcient targets for new drug trials. We tested
this approach using the streptozotocin diabetic rat, which
models human diabetic retinopathy more accurately than
the diabetic mouse (6). To capture comprehensively the
effects of diabetes on retinal vessels, we examined the
genome-wide gene expression proﬁle of the vessels, which
had not been investigated previously. The results of gene
proﬁling can be translated to human diabetes because
changes in gene expression can be studied accurately in
postmortem human retinas (7,8), at variance with bio-
chemical and posttranslational changes (8). We studied
rats with 6-month duration of diabetes to capture events
reﬂecting the ongoing injury induced by diabetes as well as
the adaptive or maladaptive response to the injury that
precedes capillary obliteration. The latter increases in the
rat after 8–9 months of diabetes (3,9).
To identify the abnormalities with pathogenic impor-
tance, we compared the molecular effects of drugs well
documented to prevent the histological features of mi-
croangiopathy in the diabetic rat. We reasoned that path-
ways that are attenuated by more than one drug and have
relevant biological consequences can be attributed a can-
didate pathogenic role, to be veriﬁed and pursued in
successive studies. In this work, we studied the aldose
reductase inhibitor (ARI) sorbinil and aspirin because they
protect the retinal vessels of diabetic rats (10,11) likely
through different mechanisms. Sorbinil inhibits the ﬁrst
enzyme of the polyol pathway, which is activated when
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DIABETES, VOL. 58, JULY 2009 1659glucose levels are high, and can damage cells by multiple
mechanisms (12). Aspirin is a pleiotropic drug that pro-
tects the retinal vessels against diabetes in multiple spe-
cies (11,13) through mechanisms that do not appear to
include its antiplatelet effects (11), but are otherwise
unsettled. There was a reasonable expectation that the
effects of the two drugs on molecular pathways would
show differences as well as similarities and that the
similarities, in turn, could identify essential pathways to be
silenced or attenuated to attain prevention of the vascular
damage induced by diabetes.
RESEARCH DESIGN AND METHODS
Procedures involving animals were approved by the animal care and use
committee of the Schepens Eye Research Institute. Male Sprague-Dawley rats
(5 weeks of age; Taconic Farms, Hudson, NY) were randomly assigned to one
of the following groups: control, diabetic, diabetic treated with sorbinil (65 mg 
kg
1  day
1; gift of Pﬁzer, Groton, CT), and diabetic treated with aspirin (30
mg  kg
1  day
1). Induction of diabetes with streptozotocin, administration
of sorbinil and aspirin with the food, and treatment of diabetic rats with
maintenance insulin were as previously described (10,11). Diabetic rats and
age-matched nondiabetic control rats were studied after 3, 6, and 8 months of
diabetes. A1C, plasma salicylates levels, and retinal levels of sorbitol and
fructose were measured as previously described (6,10,11).
Isolation of retinal vessels and RNA extraction. Rat retinal vessels were
isolated by hypotonic lysis of the fresh retina, a method documented to yield
the retinal vascular network free of glia and neural contamination (10). The
two retinas of each rat were dissected and incubated in ice-cold sterile
distilled water for1ha t4°C. After incubation with DNase to dissolve DNA
released from the lysed neural and glial cells, the vascular network was
transferred to ice-cold PBS and cleaned of debris and remaining glial and
neural elements by gentle pipetting. Total RNA free of contaminating genomic
DNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA) following
the on-column DNase digestion protocol according to the manufacturer’s
instructions. The retinal vascular network was also prepared by trypsin
digestion (3) of retinas ﬁxed in formalin immediately after killing.
Oligonucleotide microarray hybridization and data analysis. Gene ex-
pression proﬁling of rat retinal vessels was performed using the GeneChip Rat
Genome 230 2.0 array (Affymetrix, Santa Clara, CA). Each sample subjected to
microarray hybridization consisted of the RNA extracted from the vessels of
both retinas of one individual rat. Because the amount of RNA was insufﬁcient
for the standard hybridization protocol, each RNA sample was subjected to a
round of ampliﬁcation (Ovation biotin system; NuGEN Technologies, San
Carlos, CA). GAGE R&R analysis documented that the ampliﬁcation proce-
dure did not introduce variance. All procedures for microarray analysis were
carried out at the Harvard Medical School/Partners Healthcare Center for
Genetics and Genomics Core Laboratory (http://www.hpcgg.org). Gene ex-
pression data were preprocessed with MAS 5.0, and probes that were
consistently labeled as absent in all samples were excluded from subsequent
analysis.
Analysis of the microarray data was performed using BADGE (Bayesian
analysis of differential gene expression; http://genomethods.org/badge), a
Bayesian approach to identify differentially expressed genes across two
experimental conditions designed to yield high reproducibility at low sample
size (14). The differential expression of each gene in two conditions is
estimated by the fold change, and evidence of differential expression is
measured by the probability that the fold change exceeds a ﬁxed threshold,
conditional on the data. To reduce the number of false positives due to
multiple comparisons, the selection of signiﬁcant changes of expression was
based on a threshold on the posterior probability speciﬁed to achieve a preset
false discovery rate, as determined by signiﬁcance analysis of microarrays
(15).
To identify the genes whose expression is affected by diabetes, only the
19,054 probe sets “present” in all samples (eight diabetic and nine controls)
were included in the analysis. Probe sets with a probability 0.985 (equivalent
to a false discovery rate 0.01) were selected as differentially expressed in
diabetes. To determine which of the diabetes-induced gene expression
changes were prevented by the two drugs, we selected the probes identiﬁed as
differentially expressed in diabetes and compared their expression in the
sorbinil-treated diabetic group (n  5) versus the control group, and in the
aspirin-treated diabetic group (n  9) versus the control group. Genes for
which the posterior probability of differential expression versus control was
0.95 were considered different from control, and the diabetes-induced
changes were thus classiﬁed as not corrected by the drug. Conversely, when
the posterior probability of differential expression versus control was 0.95,
the expression was classiﬁed as similar to control and thus normalized by the
drug. The threshold was higher than that used to identify differential expres-
sion caused by diabetes to increase the speciﬁcity of the conclusions about
the drug effects.
The probe sets differentially expressed in diabetes were annotated using
NetAffx (www.affymetrix.com/analysis), and the annotations were individu-
ally veriﬁed based on the latest UniGene cluster of the corresponding
representative sequence. The differentially expressed genes identiﬁed through
the annotation process were assigned to functional categories based on the
information provided by Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/
entrez?dbgene) and additional information from the published literature.
Real-time RT-PCR. cDNA was synthesized (8) from 1 g of total RNA
isolated from retinal microvessels and total retina of rats different from those
studied in the microarray experiments. Real-time PCR was performed as
previously described (16). Primers and probe sets for rat transforming growth
factor (TGF)-1 and ADAMTS1 (a disintegrin and metalloproteinase with
thrombospondin motif type 1) were from Applied Biosystems (Foster City,
CA). Relative expression was determined by the comparative CT method
using -actin as the endogenous control (16).
Western blotting. Fresh retinal microvessels and whole retinas were homog-
enized in RIPA buffer containing protease and phosphatase inhibitors (10).
Immunoblotting was performed as previously described (10,16). The blots
were sequentially probed for TGF- receptor 1 (TGFR1), cyclooxygenase
(COX)-1, and nuclear receptor coactivator 3 (NCoA3). Ras GTPase activating
protein (17) or -actin were used to verify protein loading. For evaluation of
Smad2 phosphorylation, blots were probed ﬁrst for phosphorylated Smad2,
stripped, and reprobed for total Smad2. The primary antibodies used are
listed in supplemental Table 1, which is available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db08-1008/DC1.
TGFR1 immunohistochemistry. Retinal trypsin digests were rehydrated in
PBS and incubated in citrate buffer (pH 6.1; Dako, Carpinteria, CA) at 95°C for
heat-mediated antigen retrieval. After permeabilization in 1% Triton X-100,
quenching of endogenous peroxidase in 3% H2O2, and blocking in 10% normal
goat serum, endogenous biotin (unmasked by the antigen retrieval procedure)
was blocked by incubation in avidin and biotin–blocking solutions (Vector
Laboratories, Burlingame, CA). The trypsin digests were then incubated
overnight at 4°C with the TGFR1 primary antibody (V-22; Santa Cruz
Biotechnology) diluted to 1 g/ml in 2% goat serum/0.1% Triton X-100 in PBS.
The antigen-antibody complexes were detected by the avidin-biotin-peroxi-
dase method (ABC Elite; Vector Laboratories) and visualized with diamino-
benzidine. Each experiment included trypsin digests from each of the four
groups of rats as well as a negative control obtained by substituting the
primary antibody with an equivalent concentration of normal rabbit IgG. The
trypsin digests were photographed at 5 magniﬁcation (AxioVision imaging
system; Carl Zeiss, Gottingen, Germany) to reconstruct the entire vascular
network from each retina (11). The networks were used to identify for each
rat four areas in the midretina with equivalent location and free of artifacts.
The four areas were photographed at 20 magniﬁcation using the same
exposure and light setting to allow for comparison among samples. For
evaluation of TGFRI immunostaining, the images were grouped in panels of
12 images each, with each panel containing images from control, diabetic, and
diabetic treated rats. The staining intensity of the capillaries within each
image was scored on a continuous scale from 0 (no staining) to 4 (highest
staining) by four masked observers. The scores attributed to each retina by
the four observers were averaged to obtain one individual ﬁnal score for each
rat. The scoring was consistent among the four observers, as indicated by an
overall coefﬁcient of variation of 17%.
Membrane attack complex immunohistochemistry. Complement activa-
tion in rat retinal vessels was evaluated by membrane attack complex
immunostaining on rat retinal sections as previously described (10).
Statistical analysis. The results of the effect of sorbinil and aspirin on
diabetes-induced gene expression changes are summarized as the number of
genes whose expression was normalized by the drug within each functional
category. The signiﬁcance of the deviation of this number from the null
hypothesis of no gene being normalized was determined by means of a
Fisher’s exact test (2  2 contingency tables). Results of Western blotting and
real-time RT-PCR are summarized as the means 	 SD; the results in the
diabetic and control group were compared by means of a two-tailed
unpaired Student’s t test. Results of TGFRI immunostaining are summa-
rized with the means 	 SD; the results in the four groups of rats were
compared with ANOVA followed by Fisher’s protected least-signiﬁcant
differences test. StatView 5.0 software (SAS Institute, Cary, NC) was used
for all analyses.
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The characteristics of the rats used in the microarray and
related studies are presented in Table 1. The microarray
study was based on 31 expression proﬁles of retinal
microvessels isolated from diabetic rats (n  8), diabetic
rats treated with sorbinil (n  5), diabetic rats treated with
aspirin (n  9), and control rats (n  9). The duration of
diabetes was 6 months. When compared with the nondia-
betic rats, the retinal vessels of the diabetic rats showed
signiﬁcantly different expression of 127 known genes (131
probe sets) and 229 expressed sequence tags (ESTs) or
genes with similarity to known genes but not yet fully
characterized. The majority of the 127 known genes (105
upregulated and 22 downregulated by diabetes) could be
grouped into several functional categories (Table 2).
The TGF- pathway in diabetic retinal vessels. There
was a prominent effect of diabetes on the expression of
genes involved in signaling by members of the TGF-
family or affected by such signaling (Fig. 1 and supplemen-
tal Table 2). A total of 20 genes could be attributed to this
category, which made the TGF- pathway the single
functional pathway most affected by diabetes in retinal
vessels. Diabetes increased the expression of the type I
receptor activin receptor–like kinase 5 (ALK-5), a widely
distributed TGF- type I receptor that in endothelial cells
signals inhibition of migration and proliferation (18).
ALK-1, a TGF- type I receptor that is expressed more
selectively in endothelium and induces migration and
proliferation (18), was not upregulated by diabetes. There
was increased expression of syndecan-2, which is upregu-
lated by TGF- and, in turn, upregulates the TGF- type I
and type II receptors (19); of CD44, also a target of TGF-
that facilitates the activation of TGF- and signaling by the
type I receptor (20); and of ubiquitin conjugating enzyme
9, the key enzyme of the sumoylation reaction, which is
known to enhance TGF- signaling (21). The diabetic
retinal microvessels showed enhanced expression of con-
nective tissue growth factor (CTGF), the main TGF-
effector in the induction of ﬁbrosis (22); and of other genes
prominently regulated by TGF-, such as tissue inhibitor
of metalloproteinase 1, the serine (or cysteine) proteinase
inhibitor heat shock protein 47, prostaglandin-endoperox-
ide synthase 1 (COX-1), the histone acetyltransferase
NCoA3, and thioredoxin-interacting protein (Txnip) (22–
25). For some of these molecules, increased expression
was conﬁrmed at the protein level (supplemental Fig. 1).
Diabetic retinal vessels showed changes in gene expres-
sion pointing to increased signaling also by bone morpho-
genetic proteins (BMPs) (Fig. 1 and supplemental Table 2).
There was increased expression of BMP receptor type 1a,
also named ALK-3 and utilized by BMP-2 (26), and of
periostin and frizzled homolog 1, both responsive to
TABLE 1
Characteristics, retinal polyol pathway activity, and serum salicylate levels of study rats
n
Body
weight (g) A1C (%)
Retinal sorbitol
(nmol/mg protein)*
Retinal fructose
(nmol/mg protein)*
Serum salicylates
(mg/l)†
Control 50 629 	 77 5.8 	 1.5 1.17 	 0.40 3.85 	 1.45 Not tested
Diabetes 47 384 	 50‡ 13.3 	 1.9‡ 12.54 	 8.64§ 65.32 	 13.16‡ Undetected
Diabetes with sorbinil 15 382 	 48‡ 12.3 	 1.4‡ 0.56 	 0.25 6.40 	 2.14 Not tested
Diabetes with aspirin 15 370 	 43‡ 12.9 	 2.9‡ Not tested Not tested 13.5 	 7.8
Data are means 	 SD. Statistical analysis was performed with ANOVA followed by Fisher’s protected least-signiﬁcant difference test.
*Measurements were performed in four rats from each group; †measurements were performed in three diabetic rats treated with aspirin and
one untreated diabetic rat; ‡P  0.0001, §P  0.01 compared with control rats.
TABLE 2
Functional clustering of the known genes differentially expressed
in retinal vessels in diabetes
Functional category
and known function* Upregulated Downregulated
TGF-/BMPs pathway
20 genes
TGF- activation 16 —
BMP activation 3 1
Oxidative stress
7 genes
Pro-oxidant 3 —
Antioxidant 2 1
Pro-/antioxidant 1 —
Inﬂammation and response to
injury
29 genes
Inﬂammatory mediators 5 —
Acute-phase response
proteins 9 —
IFN-
 pathway 8 —
Antigen presentation 3 1
Anti-inﬂammatory 3 —
Matrix and vascular remodeling
35 genes
Matrix 4 1
Cell adhesion 7 1
Actin organization 3 2
Vascular remodeling 17 —
Cell cycle
7 genes
Cell cycle progression 1 2
Cell cycle arrest 1 1
Proliferation inhibition 2 —
Apoptosis
19 genes
Proapoptotic p53 pathway 5 2
Proapoptotic 7 1
Antiapoptotic 2 2
Other
39 genes
Metabolism 8 1
Miscellaneous† 6 2
Function unknown‡ 15 7
*The 127 known genes differentially expressed in diabetes were
assigned to functional categories based on review of information
from NCBI (National Center for Biotechnology Information) Entrez
Gene integrated with data from published literature. Individual genes
are listed in all pertinent categories based on their known functions.
The complete list of the genes included in each functional category
is presented in supplemental Tables 2–8. †Includes genes related to
functions that cannot be assigned to any of the major categories; ‡as
stated in bibliographical sources.
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Facilitated BMP signaling was also suggested by the
downregulation of the homeobox C8 (Hoxc8) transcrip-
tion factor because Hoxc8 is a negative regulator of
transcription of Smad1 and other BMP-speciﬁc receptor-
regulated Smads (29). The array included probe sets for
BMP-1 through -7; only the BMP-2 transcript was detected
in all samples, and its levels were not modiﬁed by diabetes.
Of the three TGF- isoforms present in mammals, the
array showed the TGF-2 and -3 transcripts; the levels of
neither were altered by diabetes. The TGF-1 mRNA was
undetectable in all samples tested. When measured by the
more sensitive real-time RT-PCR, TGF-1 mRNA levels
were increased 1.5-fold in the retinal microvessels of
diabetic rats (P  0.04) (Fig. 2A). Increased levels of the
TGF- type I receptor ALK-5 was conﬁrmed at the protein
level (Fig. 2B). Because ALK-5 signals through Smad2 and
Smad3, we sought evidence of ALK-5 activation by mea-
suring Smad2 phosphorylation in the retinal vessels of
diabetic and control rats. We found increased Smad2
phosphorylation after both 6- and 3-month duration of
diabetes (Fig. 2C). Taken together, the data indicate that
the complete loop for TGF-1 signaling is enhanced in
diabetic retinal vessels.
To learn whether the diabetes-induced changes in the
TGF- pathway extended to nonvascular cells of the
retina, we measured the levels of the TGF-1 transcript,
TGF- type I receptor, and Smad2 phosphorylation in the
whole retina. We observed no changes induced by diabe-
tes (Fig. 3A–C).
Genes related to oxidative stress, inﬂammation, and
remodeling in diabetic retinal vessels. Diabetes in-
creased the expression of molecules that generate oxygen-
derived free radicals and decreased the expression of
antioxidants (supplemental Table 3). Similar to the aorta
of diabetic rats (30), the retinal vessels showed prominent
upregulation of Txnip, a negative regulator of the antiox-
idant thioredoxin. Diabetes also increased the expression
of genes involved in inﬂammation and response to injury
(supplemental Table 4). The gene expression program was
thus consistent with, and expanded, previous ﬁndings
pointing to the occurrence of oxidative stress and inﬂam-
mation in diabetic retinal vessels (9,31,32). Genes involved
in tissue remodeling through formation of extracellular
. .
TGF-β pathway BMPs pathway 
Notch1
Ubc9 Hoxc8 ( )
BMPR1a
(ALK3)
IFNγR2
TGFβR1
(ALK5)
receptors
enhancers / inhibitors
signaling
target genes
CD44 CTGF syndecan-2
frizzled homolog 1
TIMP1 COX1 NCoA3
Txnip
HSP47
Mxi1 Elk3
Soat1
periostin
podoplanin syndecan-2
periostin
FIG. 1. Diabetes alters the expression of multiple genes of the TGF-
pathway (left side of the panel) and BMPs pathway (right side) in rat
retinal vessels. Upregulated genes are shown in red, downregulated in
blue. The expected effect of overexpression of genes on Smad signaling
is shown by arrowed lines (stimulation) or blunt lines (inhibition). The
expected effect of downregulation of Hoxc8 is release of inhibition,
and thus activation of signaling (dotted blunt line). BMPR1a, BMP
receptor 1a; HSP47, heat shock protein 47; IFNR2, -interferon
receptor 2; Mxi1, MAX interactor 1; Soat1, sterol O-acyltransferase 1;
TIMP1, tissue inhibitor of metalloproteinase 1; Ubc9, ubiquitin conju-
gating enzyme 9.
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FIG. 2. Upregulation of the TGF-1 signaling loop in retinal vessels of diabetic rats. Total RNA and protein lysates were prepared from retinal
vessels isolated by hypotonic lysis from the retina of diabetic (D) and age-matched control (C) rats. A: TGF-1 mRNA levels assayed by
quantitative real-time PCR. Relative expression of TGF-1 mRNA was calculated by the comparative CT method using -actin as endogenous
control. Values are the means  SD of n  6 rats per group. *P  0.04. B: Representative Western blot of TGFR1 (ALK-5) and bar plot of the
quantitative analysis. Blots were probed ﬁrst for TGFR1 followed by Ras GTPase activating protein (RasGAP) as control for loading. Values are
the means  SD of n  3–5 rats per group. *P < 0.04. C: Representative Western blots of phosphorylated Smad2 (P-Smad2) and total Smad2
(Smad2) and bar plot of the P-Smad2–to–Smad2 ratio. The P-Smad2–to–Smad2 ratio was examined in the retinal vessels of rats with 6 months
(left panel) and 3 months of diabetes (right panel). The 58–60-kDa bands detected in both retinal microvessels and the positive control (;
TGF-–treated HepG2 cells) corresponds to Smad2; the 50-kDa band present in the positive control only corresponds to Smad3. The bar plot
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actin cytoskeleton were upregulated in the diabetic ves-
sels (supplemental Table 5). All changes related to actin
were in the direction of increased polymerization and
ﬁlament stability, which may contribute antiproliferative
effects (33). Additional gene expression changes induced
by diabetes pointed to inhibitory effects on cell cycle
progression and cell proliferation (supplemental Table 6).
Proapoptotic pathways in diabetic retinal vessels.
Multiple mechanisms of apoptosis appeared activated in
diabetic vessels, many not suspected previously (supple-
mental Table 7). Changes in the expression of six genes of
the p53 pathway converged in the proapoptotic direction.
Another potential mechanism for direct death signals was
the upregulation of Fas. TGF- can induce apoptosis by
multiple mechanisms (34), which include upregulation of
Fas and activation of c-Jun NH2-terminal kinase (34,35),
the expression of which was also increased in the diabetic
retinal vessels (supplemental Table 7). A potential mech-
anism for apoptosis by neglect was the downregulation of
the G-protein–coupled receptor of lysophosphatidic acid
Edg2 (endothelial differentiation gene 2), a survival factor
for multiple cell types (36).
Concordant and discordant effects of the ARI sorbi-
nil and aspirin on the diabetes-induced changes in
gene expression in retinal vessels. The sorbinil and
aspirin doses were previously documented to prevent the
development of acellular capillaries in diabetic rats
(10,11). In this study, the dose of sorbinil overnormalized
sorbitol and reduced fructose accumulation by 96% in the
retina of diabetic rats (Table 1), thus achieving almost
complete inhibition of glucose ﬂux through the polyol
pathway. The aspirin dose, known to inhibit by 90%
thromboxane B2 formation during blood clotting in rats
and thus exert an antiplatelet effect (11), resulted in serum
salicylate levels (Table 1) 10- to 20-fold lower than those
achieved by anti-inﬂammatory doses of aspirin (rev. in 11).
Sorbinil normalized the diabetes-induced expression
changes in 56% of the known genes and aspirin normalized
those in 32%; the ﬁgures for the total number of probe sets
(known genes and ESTs) were 48 and 47%, respectively.
Both sorbinil and aspirin attenuated signiﬁcantly and to
a similar extent the effects of diabetes on the TGF-
pathway (Fig. 4), preventing the expression changes of 55
and 40% of the genes, respectively. Of note, both drugs
prevented the increased expression of TGF- receptor 1
and CTGF. Likewise, sorbinil and aspirin reduced signiﬁ-
cantly and to a similar extent the effects of diabetes on
proapoptotic pathways, with concordant correction of
changes in the p53 pathway and concordant restoration of
survival signals. In contrast, sorbinil reduced the changes
in gene expression relevant to oxidative stress and inﬂam-
mation strikingly more than aspirin (Fig. 4). Sorbinil led to
normalization of expression of 71% of genes related to
oxidative stress and 62% of those related to inﬂammation,
whereas the ﬁgures for aspirin were 29 and 3%, respec-
tively (P  0.0001 for effect of sorbinil vs. aspirin on
inﬂammation-related genes). The effect of sorbinil and
aspirin on the expression of individual genes is reported in
supplemental Tables 2–8.
The effects of sorbinil and aspirin on diabetes-induced
activation of the TGF- pathway were also tested on
trypsin digests prepared from the retinas of rats with 8
months of diabetes. These preparations afforded the op-
portunity of studying the retinal vascular network ﬁxed
immediately after death and not subjected to hypotonic
lysis while fresh. Figure 5 shows that the diffuse pattern of
TGFR1 immunoreactivity was increased in the retinal
capillaries of diabetic rats compared with control rats
(P  0.05) and that both aspirin and sorbinil treatment
prevented the increase (P  0.03 and P  0.0001 vs.
diabetes, respectively), in agreement with the microarray
results (supplemental Table 2). Of note, whereas aspirin
returned TGFR1 immunoreactivity to control values (P 
0.62 vs. control), sorbinil suppressed staining intensity
below control values (P  0.015 vs. control). Phosphory-
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preparations.
The discordant effect of sorbinil and aspirin on inﬂam-
mation, as shown by the mRNA data, was consistent with
the discordant effect on the increased levels of intercellu-
lar adhesion molecule 1 in the diabetic rat retina (11) and
was conﬁrmed by data on complement activation in retinal
vessels. Supplemental Fig. 2 shows that aspirin, at vari-
ance with sorbinil (10), failed to prevent deposition of
membrane attack complex in retinal vessels of diabetic
rats.
The signature of diabetes on retinal vessels is tissue
speciﬁc. We compared the effects of diabetes on gene
expression in retinal vessels to those in Mu ¨ller cells, the
principal glia of the retina that shows signs of activation/
reactivity in both human (37) and experimental (6) diabe-
tes. We had previously examined the gene expression
proﬁle of Mu ¨ller cells in the same model used in this study
(rats with 6-month duration of streptozotocin diabetes)
and on a comparable platform (GeneChip Rat Genome
RG-U34A; Affymetrix) (16). Supplemental Table 9 shows
that the functional gene categories affected by diabetes in
retinal vessels differed from those affected in Mu ¨ller cells.
Of the genes related to TGF- that we found affected by
diabetes in retinal vessels, 80% were represented in the
RG-U34A array, but only 6% of those were affected by
diabetes in Mu ¨ller cells. Of the genes related to apoptosis
affected by diabetes in retinal vessels, 68% were repre-
sented in the RG-U34A array, and 0% of those were
affected by diabetes in Mu ¨ller cells. Only the inﬂammation-
related genes showed overexpression in both the vascular
and glial cell types (76% of the genes affected by diabetes
in the vessels were represented in the RG-U34A, and 55%
were upregulated by diabetes in Mu ¨ller cells).
DISCUSSION
The results of this work indicate that retinal microangi-
opathy in diabetic rats is the product of several molecular
pathways that are interconnected but not of equal patho-
genic importance. Attenuation of increased activity of the
TGF- pathway and apoptosis, but not of oxidative stress
and inﬂammation, appear to be required to prevent the
microangiopathy. In view of its role in wound healing,
extracellular matrix deposition, and ﬁbrosis (22), TGF-
has over the years been an obvious candidate mechanism
for the basement membrane thickening and matrix accu-
mulation that are the hallmark of diabetes on blood
vessels and vascular structures. However, the studies
pointing to a role of excess TGF- have been performed
solely in relation to diabetic nephropathy (38).
Diabetic retinopathy has not been previously linked to
excess TGF- signaling, likely because the link has been
more difﬁcult to capture. We found increased TGF- and
TGF- signaling selectively in microvessels but not in cells
more abundantly represented in the retina, such as Mu ¨ller
glial cells (16) or neurons, that would make an increase
manifest in whole retinal extracts (this work). The few
suggestions to date of a contribution of TGF- to diabetic
retinal microangiopathy have come from the observations
that the retinas of diabetic rats show the presence of
oncofetal ﬁbronectin (39), an isoform typically stimulated
by TGF- during tissue healing and remodeling, and the
retinas of diabetic patients show expression of CTGF in
pericytes, a shift to the vascular compartment from the
microglial location of CTGF in the retinas of nondiabetic
individuals (40). Our ﬁnding of increased Smad2 phos-
phorylation indicates that increased TGF- signaling does
in fact occur in retinal vessels of diabetic rats, and the
concordant attenuation of such signaling by drugs that
protect the vessels from the effects of diabetes through
different mechanisms suggests that the increased signaling
contributes to the vascular pathology. It may be argued
that the diabetic retinal vessels showed overexpression of
inﬂammation-related genes, whereas TGF- is viewed, in
general, as anti-inﬂammatory. In this respect, the in-
creased TGF-1 expression and activity in diabetes could
even represent a compensatory response and, as such, be
protective for the retinal vessels. However, the ﬁnding that
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but only sorbinil reduced inﬂammation, indicates that the
TGF- pathway was upregulated independently of the
genes related to inﬂammation. This agrees with ﬁndings in
Mu ¨ller cells, which show in diabetic rats changes in the
expression of genes related to inﬂammation but not to
TGF- (16). Fibrosis is not necessarily driven by inﬂam-
mation, which might explain the general lack of efﬁcacy of
anti-inﬂammatory mediators in the treatment of ﬁbrotic
disease (41). In diabetes in particular, TGF- upregulation
could be induced and sustained by high glucose levels,
which stimulate TGF- promoter activity in vascular cells
(42).
Comparison of the effects of sorbinil and aspirin led to
the identiﬁcation of the signature of the polyol pathway on
retinal vessels. The ARI prevented or attenuated changes
in all functional categories of genes, indicating that the
polyol pathway mediates most molecular abnormalities
induced by hyperglycemia in rat retinal vessels, including
TGF- overexpression. The role of the polyol pathway in
mediating glucose-induced increases in TGF- has been
documented in cultured cells (43). Only the ARI, and not
aspirin, prevented the pro-oxidant and proinﬂammatory
changes in gene expression, consistent with the discor-
dant effects of the two drugs on other indicators of
diabetes-induced oxidative stress and inﬂammation (this
work and 10,11). This ﬁnding, combined with the known
pro-oxidant effects of the polyol pathway (44) and the fact
that reactive oxygen species—induced by hyperglycemia
or other stimuli—beget inﬂammation (45), points to the
combination of oxidative stress and inﬂammation as the
distinct signature of the polyol pathway on retinal vessels.
The effects of aspirin indicated that attenuation of
pro-oxidant and proinﬂammatory gene expression is not
necessary to prevent retinal vascular cell apoptosis and
vessel histopathology (11) in diabetes. We cannot exclude
that aspirin may have attenuated aspects of inﬂammation
not reﬂected in the gene expression data, but we note that
the concentration of aspirin achieved in our rats (two
orders of magnitude lower than those exerting typical
anti-inﬂammatory effects) (rev. in 11) also failed to atten-
uate complement deposition in diabetic retinal vessels.
However, it remains conceivable that attenuation of oxi-
dative stress and/or inﬂammation may be sufﬁcient to
prevent retinopathy if these processes in diabetes are
upstream of, and contribute to, apoptosis. What the effect
of aspirin highlights is that in diseases resulting from the
contribution of multiple pathogenic events, the attenua-
tion of some of the events is sufﬁcient to prevent the
ultimate phenotype, despite persistence of the other
known contributors. An example of such interplay was
recently documented in a model of Alzheimer’s disease
(46). The mechanism(s) whereby aspirin attenuated the
effects of diabetes on the TGF- and pro-apoptotic path-
ways in retinal vessels remain speculative. The dose
effective in our diabetic rats was 20-fold lower than the
dose reported to decrease the excess TGF- and CTGF
expression induced by diabetes in the rat kidney and by
high glucose in cultured mesangial cells (47). Comparison
with the selective antiplatelet agent clopidogrel had sug-
gested that our dose of aspirin protects retinal vessels in
diabetes by mechanisms other than antiplatelet activity
(11). Aspirin could have worked by inhibiting the activity
of COX-1 in vascular cells, which expressed higher levels
of the enzyme in diabetes. However, it is not known
whether increased COX-1 is harmful to vascular cells, and
the fact that aspirin prevented the overexpression of
COX-1 (not a previously known effect of aspirin) suggests
that the effects on COX-1 were downstream of some other
beneﬁcial effect. At concentrations consistent with those
achieved in our experiments, aspirin induces NO release
from endothelial cells (48).
Our ﬁndings have several translational implications.
Knowledge that the combination of oxidative stress and
inﬂammation is the distinct signature of the polyol path-
way on retinal vessels makes it possible to seek such a
signature in human diabetes to help determine whether
there is a rationale for adjunct therapy with ARIs. The
action of aspirin, which prevents the vascular histopathol-
ogy resulting from a complex process by attenuating only
selected pathways, establishes a valuable paradigm for
development of diversiﬁed drug approaches to the com-
plications of diabetes. The observation that increased
TGF- signaling begins early in diabetic retinal vessels
proposes that capillary remodeling also begins early. Early
onset of pathological remodeling can be one of the reasons
for the “memory” that retinal vessels carry of exposure to
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FIG. 5. Increased TGFRI immunoreactivity in retinal vessels of
diabetic rats is prevented by sorbinil and aspirin treatments. TGFRI
was detected by immunohistochemistry in retinal trypsin digests from
diabetic rats (8 months of diabetes duration), diabetic rats treated
with sorbinil or aspirin, and age-matched control rats. The effect of
diabetes and of the two drugs on TGFRI immunostaining was quanti-
tated by four masked observers. A–C: Representative photographs of
midretina ﬁelds showing TGFRI immunostaining of retinal capillar-
ies. A: Control, score 2.0  0.7 (mean  SD of scores by the different
masked observers). B: Diabetes, score 3.8  0.04. C: Diabetes treated
with sorbinil, score 1  0.0. D: Diabetes treated with aspirin, score
2.3  0.7. E: Negative control. Scale bar  100 microns. F: Bar plot of
the quantitative analysis of staining intensity. Values are the means 
SD of the ﬁnal scores computed for each individual rat. C, control rats,
n  11; D, diabetic rats, n  10; DSor, diabetic rats treated with
sorbinil, n  6; DAsa, diabetic rats treated with aspirin, n  6. *P 
0.05 vs. control rats; †P < 0.02 versus control rats, diabetic rats, and
diabetic rats treated with aspirin, ‡P < 0.04 versus diabetic rats.
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reversibility of even the initial lesions of diabetic retinop-
athy and justiﬁes emphasis on prevention (5). Targeting
the TGF- pathway may become a rational strategy in the
prevention of the two main microvascular complications
of diabetes, retinopathy and nephropathy. In view of the
homeostatic importance of TGF-, the targeting modali-
ties would need not to interfere with physiological activity.
Partial attenuation of overactivity appears to be sufﬁcient
to limit the consequences on tissues. Phenotypes attribut-
able to increased TGF- signaling can be rescued by
inactivation of a single TGF-1 allele (50), and in our study
prevention of retinal diabetic microangiopathy did not
require complete normalization of gene expression
changes in the TGF- pathway. Angiotensin II blockers
may prove effective anti–TGF- drugs insofar as they were
recently reported to reduce the progression of vascular
pathologies caused by excessive TGF- signaling (51).
This effect of angiotensin II blockers, coupled with our
ﬁndings of an overactive TGF- pathway in diabetic reti-
nopathy, may need to be taken into account in interpreting
the encouraging results obtained with candesartan in the
primary prevention of retinopathy in normotensive type 1
diabetic patients (52). Orally active inhibitors of TGF-
signaling are in development (53) and would add options
for highly targeted interventions. The next steps in these
studies are to deﬁne the effects of selective normalization
of TGF- signaling in retinal vessels and ascertain whether
the TGF- pathway is overactive in human diabetic
retinopathy.
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